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Summary: 
Following the national introduction of the rotavirus vaccine in Kenya, our impact 
evaluation across two surveillance sites indicates a substantial reduction in 
childhood hospitalisation due to rotavirus-associated and all-cause severe diarrhoea. 
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ABSTRACT 
 
Introduction: Monovalent rotavirus vaccine, RotarixTM, was introduced in Kenya in 
July 2014, is recommended to infants as oral doses at ages 6 and 10 weeks. A multi-
site study was established in two population based surveillance sites to evaluate 
vaccine impact on the incidence of rotavirus-associated hospitalisations (RVH). 
 
Methods: Hospital-based surveillance was conducted from January 2010 to June 2017 
for acute diarrhoea hospitalisations among children aged <5 years in two health 
facilities in Kenya. A controlled interrupted time series analysis was undertaken to 
compare RVH pre and post vaccine introduction using rotavirus negative cases as a 
control series.  The change in incidence post vaccine introduction was estimated from 
a negative binomial model that adjusted for secular trend, seasonality and multiple 
health worker industrial actions (strikes).  
Results: Between January 2010 and June 2017 there were 1513 and 1652 diarrhoea 
hospitalisations in Kilifi and Siaya; among those tested for rotavirus, 28% (315/1142)  
and 23% (197/877) were positive, respectively.  There was a 57% (95% CI: 8 to 80) 
reduction in RVH observed in the first year post vaccine introduction in Kilifi and a 
59% (95% CI: 20 to 79) reduction in Siaya. In the second year, RVH decreased further 
at both sites, 80% (95% CI: 46 to 93) reduction in Kilifi and 82% reduction in Siaya (95% 
CI: 61 to 92), and this reduction was sustained at both sites into the third year.   
Conclusions: A substantial reduction of RVH and all-cause diarrhoea has been 
observed in two demographic surveillance sites in Kenya within 3 years of vaccine 
introduction.  
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Introduction 
 
Rotavirus is a major contributor to severe diarrhoea illness and related mortality, 
especially in low and middle income countries[1–3]. Global estimates suggest that in 
2013,  rotavirus accounted for 215000 or 3.4% of all deaths in children aged <5 years[4]. 
In 2009, the World Health Organisation (WHO) recommended that all countries, 
especially those with high diarrhoea associated child mortality rates, implement 
rotavirus immunisation programmes[5]. Kenya adopted this recommendation in July 
2014[6,7]. Since then, two doses of live attenuated rotavirus vaccine (RotarixTM), in 
addition to  oral polio, pneumococcal conjugate (PCV) and pentavalent vaccines, have 
been recommended to children in Kenya, targeted at 6 and 10 weeks of life, as part of 
the routine child immunisation programme[8,9]. It was estimated that introduction of 
this vaccine in Kenya would avert over 60,000 deaths and over 200,000 hospitalisations 
among children aged <5 years during the first 20 years of introduction[10]. Following 
vaccine introduction, we used demographic and hospital data from two population-
based surveillance sites in Kenya to estimate the impact of the programme on 
rotavirus hospitalizations in children <5 years. 
 
Methods 
 
Geographical Location 
 
The study was conducted in two regions with established demographic surveillance 
systems (DSS):  the Kilifi Health and Demographic Surveillance System[11] (Kilifi 
HDSS), which is located on the Kenyan coast, and the Kenya Medical Research 
Institute (KEMRI) and the Centers for Disease Control and Prevention (CDC) Health 
and Demographic Surveillance System (Siaya HDSS) [12] in rural western Kenya near 
Lake Victoria. Hospitalisation, diarrhoea and rotavirus counts for children under 5 
years of age were obtained from two government hospitals: Kilifi County Hospital 
located in the Kilifi HDSS and Siaya County Referral Hospital located in the Siaya 
HDSS. 
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Vaccine introduction and coverage 
 
Rotavirus vaccine was introduced into the childhood vaccination programme in both 
Kilifi and Siaya counties in July 2014. Children who were aged 6 weeks or younger or 
born after the start of the rotavirus immunisation programme were eligible to receive 
one dose at 6 weeks and one dose at 10 weeks, though vaccine stock outs in November 
and December 2014 kept some eligible children from receiving vaccine. There was no 
catch-up campaign in either Kilifi or Siaya.  
 
In Kilifi HDSS, vaccinations have been recorded comprehensively since 2008 through 
a network of approximately 30 health facilities (both private and public) 
(Supplementary Figure1), as part of the Kilifi vaccine monitoring study (KiVMS)[13]. 
In Siaya HDSS over 20 health facilities administer vaccines to children 
(Supplementary Figure2); since 2007, immunisation data have been collected for 
children aged <5 years during household data collection rounds, which occur 2-3 
times per year[12]. In addition, the vaccination status of children enrolled in the 
rotavirus surveillance at Siaya County Referral Hospital is recorded at the time of 
hospital admission.  In both sites, card confirmed vaccine information was captured 
by the field staff 
 
Rotavirus surveillance 
 
In 2009, to prepare for vaccine introduction[12,14], rotavirus surveillance was 
intensified at Siaya County Referral Hospital among children aged < 5 years who 
presented with three or more loose stools within a 24-hour period and one or more 
vomiting episodes. In Kilifi, rotavirus surveillance was initiated in late 2009 in 
inpatient children aged less than 13 years with three or more loose stools within a 24-
hour period. Parents of eligible children were briefed on the potential risks and 
benefits before of the study before being asked to give consent by the study team. Stool 
samples were collected from eligible children, whose parents provided  voluntary 
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informed consent, and tested for rotavirus antigen by Enzyme-Linked 
Immunosorbent Assay (ELISA), as described previously[14,15].  
 
Surveillance was interrupted by 12 industrial actions (strikes), including 7 before and 
5 after rotavirus vaccine introduction, by different cadres of  health care workers as 
indicated in supplementary Table1.   
 
Statistical analysis 
 
We used a controlled interrupted time series analysis in which rotavirus negative 
diarrhoea hospitalisations acted as the control series to compare monthly RVH before 
and after rotavirus vaccine introduction in children <5 years of age. Specifically, RVH 
from the period 54 months prior (January 2010 to June 2014) were compared with 
hospitalisations from the period 36 months post (July 2014 to June 2017) vaccine 
introduction at each facility. For a month in which <100% of diarrhoea cases were 
tested for rotavirus, the number of rotavirus-positive cases was scaled by multiplying 
the total  number of diarrhoea cases by the proportion rotavirus positive among those 
tested in that month.  
 
A negative binomial regression was used to estimate the change in rotavirus 
hospitalisations in the first year (July 2014-June 2015), second year (July 2015-
June2016) and third year (July 2016-June 2017) post vaccine introduction. The model 
included rotavirus negative diarrhoea (the control series) as an offset, and calendar 
month and health worker industrial actions as covariates. Lag-1 Newey-West 
standard errors were used to adjust for autocorrelation[16].  A similar analysis was 
conducted for all cause diarrhoea using non-diarrhoea hospitalisations  as the control 
series.  
 
For the analysis of rotavirus positive diarrhea, a sensitivity analysis was conducted 
using a synthetic control[17–19] in the regression model instead of rotavirus negative 
cases. The synthetic control was generated by weighting three conditions (rotavirus 
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negative diarrhoea, pneumonia, malaria)—using SYNTH[20] command in Stata—so 
that their sum closely resembled the pre-vaccine rotavirus positive time series.   
 
All statistical analyses were conducted using Stata13.1 software, (Stata Corporation, 
College Station, TX, USA). All datasets, Stata files and related documentation are 
available on an online data repository (https://doi.org/10.7910/DVN/PH4COG 
)[21]. 
 
Ethics Review 
Ethical approval to conduct this study was granted by the KEMRI Scientific and 
Ethics Review Unit (SERU)  (SSC # 3049)  and the CDC’s institutional review board 
(protocol #6968). 
 
Results 
Incidence and Seasonality 
 
During the study period, there were 1513 and 1652 diarrhoea hospitalisations in Kilifi 
County Hospital and Siaya County Referral Hospital, respectively. In Kilifi, 1142 
(75.5%) of the diarrhoea cases were tested and among those tested 315 (27.6%) were 
positive for rotavirus.  In Siaya, 877 (53.1%) were tested and 197 (22.5%) were positive 
for rotavirus.   
 
The proportion of children living in the study areas who received rotavirus vaccine 
increased with time. Between 2014 (year of introduction) and 2017, the proportion of 
aged <1 year with at least one dose increased from 31% to 73% in Kilifi and 16% to 
75% in Siaya; the proportion fully vaccinated (two doses) in 2017 was 65% in Kilifi and 
62% in Siaya. The highest coverage among infants was observed in 2016. Among 
children aged 12-23 months, the proportion with at least one dose increased from 0% 
to 86% in Kilifi and 0% to 94% in Siaya; coverage with two doses in 2017 was 84% and 
92% repectively (Figure 1). The lowest proportions of vaccinated children were 
observed in 2014 across both sites due to vaccine roll-out in mid-year and the 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz912/5572563 by U
niversity of W
arw
ick user on 25 Septem
ber 2019
 8 
 
unexpected stock-out.  Among vaccinated children, the median age at receipt of the 
first dose was 6 weeks (interquartile range [IQR] 6 to 7) in Kilifi and 6 weeks (IQR: 6 
to 7) in Siaya; median at age receipt of the second dose was 10 weeks (IQR 10 to 13) in 
Kilifi and 10 weeks (IQR 10 to 12) in Siaya.  
 
Across the two demographic surveillance systems, overall diarrhoeal illness and 
rotavirus-specific illness displayed seasonal patterns which were dampened after the 
introduction of the vaccine (Figure 2). Siaya generally recorded higher  diarrhoea and 
rotavirus associated diarrohoea incidences compared to Kilifi in the pre-vaccination 
era (Tables 1 and 2).  In Kilifi, the highest numbers of rotavirus cases were recorded 
from April/May to September/November of the same year (Figure 2a). In Siaya, the 
RVH season began earlier in the year, usually in January /February (Figure 2b). At 
both sites, there was a declining trend in annual incidence of diarrhoea and RVH that 
began prior to the rotavirus immunization programme and continued following 
introduction of vaccine (2015-2017). During the years affected by industrial actions of 
health workers (Supplementary Table1) lower rotavirus incidence rates were recorded 
at both sites (Table 2).   
 
Impact of vaccine using rotavirus negative control series 
 
In Kilifi, we observed reduced rates of RVH among KHDSS resident children <5 years 
throughout the post vaccination period (Table 3 and Figure 3). When compared with 
rates from the pre-vaccine era, reductions were observed during the first year (57%, 
95% CI: 8.0- 80.0), the second year (80%, 95% CI: 46-93) and third year (76%, 95% CI: 
56-87) (Supplementary Figure 3(a)).  Similarly, in Siaya there were reductions in the 
first year (59%, 95% CI: 20-79), second year (82%, 95% CI: 61-92) and third year (81%, 
95% CI: 7-96) post vaccine introduction (Supplementary Figure 3(b)).  
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Impact of vaccine on all-cause diarrhoea  
 
When examining trends in all-cause diarrhoea using non-diarrhoea hosptializations 
as the control series,  significant reductions were observed at both sites in post-vaccine 
introduction years (Table 3) , though by a smaller magnitude compared to reductions 
in RVH. In Kilifi, impact of the vaccine on all-cause diarrhoea increased from 41% 
(95% CI: 16 to 59) in the first year to 48% (95% CI: 40 to 55) and 46% (95% CI: 34 to 55) 
in the second and third year respectively (Supplementary Figure 3(e)). In Siaya, there 
was a 41% (95% CI: 27 to 52) reduction of all cause diarrhoea in the first year followed 
by 60% (95%CI: 43 to 72) in the second year and and 62% (95% CI: 38 to 77) reduction 
in  the third year (Supplementary Figure 3(f)). 
 
Impact of the vaccine on RVH using synthetic controls 
 
The associated weights for each component of the synthetic control are shown in 
Supplementary Table 2, and the results of vaccine impact analysis  in Supplementary 
Table 3 and Supplementary Figure 3. Vaccine impact estimates from this analysis are 
similar to those presented in Table 3, except that estimate for the last year in Kilifi was 
slightly lower than the corresponding estimate in Table 3. In Kilifi, impact of the 
vaccine  was 67% (95% CI: 27 to 85) in the first year, 86% (95% CI: 64 to 94%) in the 
second year and 69% (95% CI: 45 to 83) in the third year. Similarly, in Siaya vaccine 
impact  increased from 68% (95% CI: 33 to 84) in the first year to 89%  (95% CI: 68 to 
96) in the second year and 82% (95% CI: 8 to 96%) in the third year. 
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Discussion 
 
We present results of an evaluation of the impact of rotavirus vaccine in Kenya using 
data from two population-based surveillance systems. Kenya introduced RotarixTM 
vaccine into the national programme as a 2 dose schedule (6 and 10 weeks of age).  We 
observed that most vaccinated children at both sites received either one or both doses 
of the vaccine within 3 weeks of the recommended time of vaccination. We estimate 
impact of the vaccine on RVH using non rotavirus hospitalisations and synthetic 
controls to control for any secular trends unrelated to the vaccine. Despite differences 
in the incidence of rotavirus disease in Kilifi and Siaya, as observed in this study and 
previous studies[15,22], the impact of vaccination was similar at both sites.  In the first 
year post vaccine introduction, RVH declined by close to 60% in both Kilifi and Siaya, 
and all-cause diarrhoea declined by over 40% at both sites. In the second year of 
vaccination RVH further declined to over 80%, and this decline was sustained into the 
third post-vaccine introduction year with increasing coverage. Similarly, the positive 
impact of the vaccine on all-cause diarrhoea increased in the second and third years 
to as high as 60% reduction thus providing clear evidence of the substantial public 
health value of rotavirus immunization. These reductions suggest that vaccination of 
children aged less than two years, who are most likely to transmit rotavirus, optimizes 
direct and indirect protection against severe diarrhoeal infections.  
 
Our estimates of rotavirus vaccine impact in the first year of vaccination are consistent 
with estimates from other African studies, which have ranged between 54% and 61% 
reduction for RVH and between 43% and 48% for all-cause diarrhoea 
hospitalizations[23,24]. The same studies reported increasing impact in the second 
year of vaccination as was observed in our study.  
  
Using the average of the 2013’s Kilifi and Siaya rotavirus disease incidence estimates 
(166 per 100,000 per year) to represent disease incidence in Kenya in the absence of 
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rotavirus vaccination, and assuming an under 5 population size of 6 million[25], an 
80% vaccine impact equates to approximately 8,000 rotavirus-related hospitalisations 
prevented per year in Kenyan children <5 years. Over 20 years this corresponds to 
160,000 hospitalisations prevented, which is similar to a previous estimate of 
200,000[10].  
 
Our study was impacted by health worker industrial actions and a pre-vaccine secular 
trend in RVH, possibly reflecting improved sanitation and hygiene[26]. To mitigate 
against these potential sources of bias we included the monthly rotavirus negative (or 
synthetic control) as an offset term in our regression model. Additionally, we excluded 
the longest strike period (July-December 2017) from our analysis. An important 
assumption of this analysis is that the rotavirus negative count reflects the 
counterfactual trend in rotavirus positive cases that would have been observed in the 
absence of vaccination.  Another limitation we considered was that only a fraction 
(75% in Kilifi and 53% in siaya) of eligible diarrhoea cases were tested for rotavirus 
which represents another potential source of bias. To adjust for this, we imputed the 
number of rotavirus cases by multiplying the number of diarrhoea cases by the 
fraction that tested positive. This imputation assumes that the fraction rotavirus-
positive is the same in those tested as it is in those who were not tested, and may itself 
introduce bias, particularly if the fraction tested changes over time.  
 
In conclusion, results from this study suggest that the burden of rotavirus and all-
cause diarrhoea declined substantially in Kenyan children in two regions of Kenya 
after rotavirus vaccine introduction. The estimates from this study represent total 
impact; indicating potential herd effects of the vaccine. Our estimates of vaccine 
impact on rotavirus and all-cause diarrhoea were consistent across the two study sites, 
and are consistent with findings from other African countries. These results contribute 
to the global estimates of rotavirus vaccine impact, especially in low and middle-
income countries, and will likely inform future decisions by policy makers on 
rotavirus vaccination .  
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Figures Legends: 
 
Figure 1: Proportion of children aged <5 years who received 2 doses of  rotavirus 
vaccine between 2014 and 2017 in Kilifi and Siaya demographic surveillance sites.  
 
Figure 2: Monthly counts of diarrhoea and rotavirus positive cases in Kilifi and Siaya 
from January 2010 to June 2017. Industrial actions by health workers are indicated by 
grey shading and the start of rotavirus vaccination in Kenya (July 2014)  is indicated 
by an arrow. 
 
Figure 3: Monthly counts of rotavirus positive cases (red line) and the counterfactual 
number of cases (dashed lines) predicted by the model assuming no vaccine 
introduction. The vertical line indicates the time of vaccine introduction in Kenya (July 
2014). 
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TABLES 
 
Table 1: Monthly diarrhoea and rotavirus counts and incidence rates per 100,000 children per year by site prior to rotavirus vaccine 
introduction (January 2010 - June 2014). Rotavirus incidence rates are scaled as described in methods.  
 
 Kilifi Siaya 
 
Person 
Years Diarrhoea 
Rotavirus 
(Observed) 
Rotavirus 
(scaled) 
Diarrhoea 
Incidence 
Rotavirus 
Incidence 
Person 
Years Diarrhoea 
Rotavirus 
(Observed) 
Rotavirus 
(Scaled) 
Diarrhoea 
Incidence 
Rotavirus 
Incidence 
             
January 20041 90 19 22 449 110 8169 218 22 49 2669 600 
February 20041 86 12 16 429 80 8169 220 39 70 2693 857 
March 20041 103 15 19 514 95 8169 136 25 51 1665 624 
April 20041 113 21 29 564 145 8169 116 16 30 1420 367 
May 20041 125 22 29 624 145 8169 160 24 37 1959 453 
June 20041 158 37 47 788 235 8169 164 9 18 2008 220 
July 16055 118 38 52 735 324 6769 111 8 13 1640 192 
August 16055 78 39 46 486 287 6769 73 8 13 1078 192 
September 16055 65 25 33 405 206 6769 65 9 12 960 177 
October 16055 58 12 14 361 87 6769 70 7 11 1034 163 
November 16055 68 5 6 424 37 6769 73 6 12 1078 177 
December 16055 40 4 6 249 37 6769 81 9 19 1197 281 
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Table 2: Annual diarrhoea and rotavirus incidence rates per 100,000 children under 5 years in Kilifi and Siaya, Kenya.   
 
 
 Kilifi Siaya 
Year 
Population 
Estimate Diarrhoea 
Rotavirus 
(Observed) 
Rotavirus 
(scaled)* 
Diarrhoea 
Incidence 
Rotavirus 
Incidence 
Population 
Estimate Diarrhoea 
Rotavirus 
(Observed) 
Rotavirus 
(scaled)* 
Diarrhoea 
Incidence 
Rotavirus 
Incidence 
             
2010 47746 319 70 93 668 195 21885 500 78 124 2285 567 
2011 48083 323 74 90 672 187 20953 446 53 107 2129 511 
2012 48412 213 56 70 440 145 19947 201 26 50 1008 251 
2013 48414 140 31 42 289 87 18439 218 21 45 1182 244 
2014 47835 196 31 40 410 84 16803 162 7 13 964 77 
2015 47943 157 39 51 327 106 14613 71 8 8 486 55 
2016 46109 116 12 13 252 28 12806 39 2 2 305 16 
2017 23310 49 2 3 210 13 10891 15 2 2 138 18 
 
 
* Rotavirus incidence rates are scaled as described in methods 
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Table 3: Incidence rate ratios (IRR) comparing rotavirus and diarrhoea incidence 
pre (Jan 2010-June 2014) and post vaccine (July 2014- June 2017) introduction in a 
vaccine impact study in Kenya 2010-2017*.  
 
 
* See Methods for statistical details. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  Rotavirus  All cause Diarrhoea 
 Post-vaccine period IRR 95% CI p-value  IRR 95% CI p-value 
         
Kilifi July 14- June 15 0.43 0.20-0.92 0.031  0.59 0.41-0.84 0.003 
 
July 15- June16 0.20 0.07-0.54 0.002  0.52 0.45-0.60 <0.001 
July 16- June17 0.24 0.13-0.44 <0.001  0.54 0.45-0.66 <0.001 
        
Siaya July 14- June 15 0.41 0.21-0.80 0.009  0.59 0.48-0.73 <0.001 
 
July 15- June16 0.18 0.08-0.39 <0.001  0.40 0.28-0.57 <0.001 
July 16- June17 0.19 0.04-0.93 0.040  0.38 0.23-0.62 <0.001 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz912/5572563 by U
niversity of W
arw
ick user on 25 Septem
ber 2019
 21 
 
Figure 1 
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Figure 2 
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Figure 3 
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